Maurice S Swanson from 3131 58Th Blvd, Gainesville, FL 32606, age 73, Phone: 3523766374

Resumes

Professor

view source

Location:

Gainesville, FL

Industry:

Higher Education

Work:

University of Florida
Professor

Education:

University of California, Berkeley
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy

Skills:

Biochemistry
Cell Culture
University Teaching
Science
Molecular Biology
Student Affairs
Higher Education
Molecular Cloning
Teaching
Research
Cell Biology
Life Sciences
Genetics
Pcr
Western Blotting
Rna Biology
Microscopy

Maurice Swanson

view source

Work:

Ech Company 1989 - 1993
Retired U.s Army 1Sg

Medicine Doctors

Maurice G. Swanson

view source

Specialties:

Family Medicine

Work:

Premier HealthNetMonroe Medical Center
20 Overbrook Dr STE C, Monroe, OH 45050
5135397356 (phone), 5135390205 (fax)

Education:

Medical School
Southern Illinois University School of Medicine
Graduated: 1988

Procedures:

Arthrocentesis
Destruction of Benign/Premalignant Skin Lesions
Electrocardiogram (EKG or ECG)
Skin Tags Removal
Vaccine Administration

Conditions:

Acne
Acute Bronchitis
Acute Conjunctivitis
Acute Upper Respiratory Tract Infections
Anemia

Languages:

English

Description:

Dr. Swanson graduated from the Southern Illinois University School of Medicine in 1988. He works in Monroe, OH and specializes in Family Medicine. Dr. Swanson is affiliated with Atrium Medical Center and West Chester Hospital.

Us Patents

Methods And Compositions For Treatment Of Diseases Associated With Aberrant Microsatellite Expansion
view source
US Patent:

20080213182, Sep 4, 2008
Filed:

Mar 10, 2005
Appl. No.:

10/591883
Inventors:

Maurice S. Swanson - Gainesville FL, US
Rahul N. Kanadia - Gainesville FL, US
Charles A. Thornton - Rochester NY, US
Assignee:

UNIVERSITY OF FLORIDA RESEARCH AND GRADUATE PROGRAMS - GAINESVILLE FL
International Classification:

A61K 35/76
A61P 21/00
A01K 67/027
C12N 5/06
US Classification:

424 92, 424 932, 800 9, 435354
Abstract:

The present invention provides methods and compositions for the treatment of diseases associated with aberrant microsatellite expansions. Methods of the present invention comprise the use of recombinant adeno-associated virus vectors containing a transgene encoding at least one muscleblind protein. The present invention also provides an animal model for a disease associated with aberrant microsatellite expansion.

Compositions And Methods Related To Protein Displacement Therapy For Myotonic Distrophy
view source
US Patent:

20100190689, Jul 29, 2010
Filed:

Sep 21, 2007
Appl. No.:

12/442354
Inventors:

Charles A. Thornton - Rochester NY, US
Thurman Wheeler - Rochester NY, US
Krzysztof Sobezak - Rochester NY, US
Robert Osborne - Rochester NY, US
Jill Miller - Rockport NY, US
Maurice Swanson - Gainesville FL, US
Assignee:

University of Rochester - Rochester NY
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:

A61K 38/14
C12Q 1/68
A61K 31/7088
C12N 5/00
C07H 21/00
US Classification:

514 8, 435 6, 514 44 A, 435325, 536 245
Abstract:

Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)or poly(CCUG)RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.

Treatment Of Conditions Associated With Myotonic Dystrophy
view source
US Patent:

20210023091, Jan 28, 2021
Filed:

May 10, 2018
Appl. No.:

16/612192
Inventors:

- Atlanta GA, US
- Gainesville FL, US
- San Bruno CA, US
Maurice Scott SWANSON - Gainesville FL, US
Eric Tzy-Shi WANG - Gainesville FL, US
Lyndon LIEN - Hillsborough CA, US
International Classification:

A61K 31/5517
A61P 21/00
Abstract:

Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Examples of the GABAA receptor antagonist or inverse agonist include flumazenil, clarithromycin, a fluoroquinolone, picrotoxin, bicuculline, gabazine, cicutoxin, oenan-thotoxin, pentylenetetrazol, Ro15-4513, sarmazenil, amentoflavone, zinc, and any combination thereof.